Management of non-small cell lung cancer in the era of personalized medicine |
| |
| Affiliation: | 1. Thoracic Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ – IRCCS, Napoli, Italy;2. Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ – IRCCS, Napoli, Italy;3. Experimental Pharmacology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ – IRCCS, Napoli, Italy;4. Radiation Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ – IRCCS, Napoli, Italy;5. Interventional Radiology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ – IRCCS, Napoli, Italy;1. Clinique du Val d’Ouest, 39, chemin de la Vernique, 69130 Ecully, France;2. Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France;3. International Breast Institute of Orangerie, 11, rue Silbermann, 67000 Strasbourg, France;1. Health Technology and Services Research, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands;2. Cultural Geography, Wageningen University, PO Box 47, 6700 AA Wageningen, The Netherlands;1. Serviço de Cardiologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte – EPE, Centro Académico Medicina de Lisboa / Centro Cardiovascular da Universidade de Lisboa, Lisboa, Portugal;2. Serviço de Oncologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte – EPE, Centro Académico Medicina de Lisboa, Lisboa, Portugal;3. Serviço de Radioterapia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte – EPE, Lisboa, Portugal;1. Section of General Thoracic Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia;2. Department of Surgery Patient Safety and Data Management Program, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia;3. Division of Surgical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia;1. Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina;2. Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, North Carolina;3. Radiation Oncology Unit, Oncology Institute, Rambam Medical Campus, Haifa, Israel;4. The University of North Carolina, Chapel Hill, North Carolina;5. Division of Cardiothoracic Surgery, Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina |
| |
| Abstract: | ![]()
Despite major advances in the molecular definition of the disease, screening and therapy, non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival, depending on subtype and tumor stage. To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement. This short viewpoint describes the emerging strategies for the management of NSCLC, indicating how a personalized approach, characterized by a specific multidisciplinary involvement, implies a process that starts with early detection and includes surgery and systemic therapy. |
| |
| Keywords: | Non-small cell lung cancer (NSCLC) Personalized medicine EGFR ALK Early detection Video-assisted thoracoscopic surgery (VATS) Stereotactic ablative radiotherapy (SABR) Immunotherapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
